Aethlon Medical’s (AEMD) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Aethlon Medical (NASDAQ:AEMD) in a research note released on Monday,Benzinga reports. HC Wainwright currently has a $7.00 price objective on the medical equipment provider’s stock.

Separately, StockNews.com upgraded Aethlon Medical to a “sell” rating in a report on Wednesday, February 19th.

Aethlon Medical Stock Down 7.8 %

Aethlon Medical stock opened at $0.42 on Monday. Aethlon Medical has a 12-month low of $0.24 and a 12-month high of $1.85. The stock has a market cap of $6.00 million, a price-to-earnings ratio of -0.26 and a beta of 1.80. The business’s 50-day simple moving average is $0.63 and its 200 day simple moving average is $0.50.

Aethlon Medical (NASDAQ:AEMD) last issued its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09. As a group, sell-side analysts expect that Aethlon Medical will post -0.73 EPS for the current year.

Hedge Funds Weigh In On Aethlon Medical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AEMD. Allegiance Financial Group Advisory Services LLC acquired a new stake in shares of Aethlon Medical during the fourth quarter worth about $26,000. Virtu Financial LLC acquired a new stake in shares of Aethlon Medical during the fourth quarter worth about $81,000. Renaissance Technologies LLC acquired a new stake in shares of Aethlon Medical during the fourth quarter worth about $25,000. Sassicaia Capital Advisers LLC acquired a new stake in shares of Aethlon Medical during the fourth quarter worth about $31,000. Finally, Boothbay Fund Management LLC acquired a new stake in shares of Aethlon Medical during the fourth quarter worth about $186,000. Institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.